Loading stock data…
OABI
$2.40+0.12 (+5.26%)
After Hours$2.40+0.00 (+0.00%)· Last close Jun 9
OmniAb, Inc., a biotechnology company, licenses discovery research technology to pharmaceutical and biotech companies, and academic institutions to enable the discovery of therapeutics in the United States, Europe, Japan, China, and Canada.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
OmniAb, Inc. in the Healthcare sector is trading at $2.40. Wall Street consensus targets $7.33 (6 analysts), implying a +205.6% move over the next 12 months. The stock is currently 14% below its 52-week high of $2.79, remaining 34.8% above its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 50/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +205.6% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Anchored to each ticker's own 5-year median trailing P/E, tilted by current ROE and growth. Fair P/E = own median P/E + (ROE × 10) + (max(revenue growth, earnings growth) × 15), capped at ±30% around the historical anchor. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. Premium compounders like COST/MSFT are judged against their own multi-year norm rather than a sector median. Falls back to the sector-anchored formula (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) for recent IPOs and tickers with insufficient history (< 24 monthly samples). Result is a normalised multiple gauge — not a price target.
Current Price$2.40
Potential Downside
0%
Whystock Fair Value$2.40
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
OmniAb, Inc., a biotechnology company, licenses discovery research technology to pharmaceutical and biotech companies, and academic institutions to enable the discovery of therapeutics in the United States, Europe, Japan, China, and Canada. The compa...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
-
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-20.67%
Volume
Today's trading volume
377,085
Recent News
Companies Like OmniAb (NASDAQ:OABI) Are In A Position To Invest In Growth
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
OmniAb (OABI) Q1 2026 Earnings Transcript
OmniAb delivered a very strong start to the year, largely driven by advancement of our partner programs. The progression of these programs gives us a growing line of sight into potential for future milestones and new royalties as our partners' programs advance. In addition, our innovations and our technologies are designed to differentiate OmniAb as a licensing partner and more broadly as a business.
OmniAb, Inc. Q1 2026 Earnings Call Summary
Moby summary of OmniAb, Inc.'s Q1 2026 earnings call
OmniAb Q1 Earnings Call Highlights
OmniAb (NASDAQ:OABI) reported first-quarter 2026 results that management characterized as a “very strong start to the year,” driven primarily by clinical progress across its partner portfolio and associated milestone revenue. Partner program progress drives revenue outperformance President and CEO
OmniAb, Inc. (OABI) Reports Q1 Loss, Tops Revenue Estimates
OmniAb, Inc. (OABI) delivered earnings and revenue surprises of +40.00% and +164.13%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?